It would seem to me that RLFTF needs to NOW focus on generating sales and turning a profit off of their existing portfolio of drugs. Rather than pay more salaries and bonuses for more R&D in gene therapy. Where are the $$ going to come from to pay this person. Is RAM's vision a never ending black hole of R&D. It's time to start generating sales and moving toward a profit making enterprise. They are about to do an R/S, and we know where that will take us a year down the road. More dilution to pay for initiatives such as this. JMHO.
Market Data 
Markets 
AI
